ONS - Oncobiologics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.850000
0.000000 (0.00%)
As of 9:39AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.850000
Open0.850000
Bid0.850000 x 4000
Ask0.880000 x 800
Day's Range0.850000 - 0.850000
52 Week Range0.782000 - 2.300000
Volume6,570
Avg. Volume60,684
Market Cap27.483M
Beta0.03
PE Ratio (TTM)N/A
EPS (TTM)-1.697000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Oncobiologics Announces Randy Thurman as Executive Chairman of the Board of Directors and Lawrence A. Kenyon as Interim CEO

    Oncobiologics, Inc. (ONS) today announced that Pankaj Mohan, Ph.D., its Chairman and Chief Executive Officer (CEO), has stepped down as CEO and Chairman of the board with immediate effect. Dr. Mohan will remain a member of Oncobiologics’ board of directors and will enter into a consulting agreement with the Company to provide advisory services in connection with the development and initiation of clinical trials for ONS-5010, an innovative monoclonal antibody (mAb) product candidate under development.

  • GlobeNewswire7 days ago

    Oncobiologics Enters into First CDMO Contract

    Oncobiologics, Inc. (ONS) today announced that it has entered into a Master Services Agreement (MSA) with Sonnet BioTherapeutics, Inc., a privately held development stage biopharmaceutical company, and has officially launched its BioSymphony™ Platform based contract development and manufacturing (CDMO) business.  The terms of the MSA were not disclosed, but the MSA engages Oncobiologics to provide CDMO services for up to four drug product candidates over the next three years. “We are excited to sign our first CDMO contract to leverage our BioSymphony™ Platform capacity with development stage partners.  Our Biosymphony™ Platform capabilities have generated a great deal of interest and we look forward to leveraging our recently announced participation in the Bio2Source program to add additional partners for our CDMO services.  We believe this CDMO business, and the associated revenue, integrated with our ongoing efforts to develop our own proprietary innovative and biosimilar product candidates, will help us to reduce costs and improve efficiency to drive stockholder value," commented Pankaj Mohan, Ph.D., Chairman and CEO of Oncobiologics.

  • GlobeNewswire12 days ago

    Oncobiologics Closes Second Tranche of $15 Million Private Placement

    Oncobiologics, Inc. (ONS) (the “Company”) today announced that it has closed on the second, and final, tranche of a $15.0 million private placement of shares of its common stock and warrants that have an aggregate exercise price of approximately $20.0 million pursuant to the May 11, 2018 purchase agreement with GMS Tenshi Holdings Pte. Limited (“GMS Tenshi”), the Company’s strategic business partner and largest investor. The Company issued GMS Tenshi an additional 6,377,383 shares of its common stock and warrants to acquire up to 10,256,410 additional shares of its common stock for aggregate cash proceeds of $7.5 million.

  • GlobeNewswire16 days ago

    Stelis Biopharma and Oncobiologics to Unveil Bio2Source CDMO Offering at BIO 2018

    CRANBURY, N.J., June 04, 2018-- Stelis Biopharma and Oncobiologics, Inc. today announced that they will unveil a new contract development and manufacturing effort at BIO 2018 in Boston. Marketed under ...

  • ACCESSWIRE20 days ago

    Blog Exposure - Evogene Signs Collaboration Agreement with BASF for Development of Novel Insecticides

    LONDON, UK / ACCESSWIRE / May 31, 2018 / If you want access to our free research report on Evogene Ltd (NASDAQ: EVGN), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EVGN as the Company's latest news hit the wire. On May 29, 2018, the Company, which is a leading biotechnology organization developing novel products for life science markets, and BASF, which is one of the world's leading chemical Companies, declared on May 29, 2018, that they have signed a new collaboration agreement for the development of novel insecticides based on new binding areas (Site-of-Action or ‘SoA') on key insecticidal target proteins. Active-Investors.com is currently working on the research report for Oncobiologics, Inc. (NASDAQ: ONS), which also belongs to the Healthcare sector as the Company Evogene.

  • GlobeNewswirelast month

    Oncobiologics Reports Second Quarter Financial Results for Fiscal 2018

    CRANBURY, N.J., May 15, 2018-- Oncobiologics, Inc. today reported financial results and business highlights for its three and six months ended March 31, 2018.. Strengthened balance sheet with first closing ...

  • GlobeNewswirelast month

    Oncobiologics Announces $15 Million Private Placement Offering

    Oncobiologics, Inc. (ONS) (the “Company”) today announced that on May 11, 2018, it entered into a purchase agreement with GMS Tenshi Holdings Pte. Limited (“GMS Tenshi”), the Company’s strategic business partner and largest investor, providing for the private placement of $15.0 million of shares of its common stock and warrants that have an aggregate exercise price of approximately $20.0 million. The closing of the sale of the first tranche of this private placement for an aggregate of 6,377,383 shares of Oncobiologics common stock and warrants to acquire up to 10,256,410 additional shares of its common stock for aggregate cash proceeds of $7.5 million occurred today.  The common shares were sold at the ONS consolidated closing bid price on May 11, 2018, plus a premium to reflect the purchase of the warrants.

  • GlobeNewswire2 months ago

    Oncobiologics Appoints Randy Thurman to Board of Directors

    CRANBURY, N.J., April 17, 2018-- Oncobiologics, Inc. today announced the appointment of Randy Thurman to its board of directors, effective April 13, 2018. At the same time, Oncobiologics also announced ...

  • Why Oncobiologics Inc’s (NASDAQ:ONS) Ownership Structure Is Important
    Simply Wall St.2 months ago

    Why Oncobiologics Inc’s (NASDAQ:ONS) Ownership Structure Is Important

    In this analysis, my focus will be on developing a perspective on Oncobiologics Inc’s (NASDAQ:ONS) latest ownership structure, a less discussed, but important factor. A company’s ownership structure is oftenRead More...

  • GlobeNewswire3 months ago

    Oncobiologics Appoints Dr. Joerg Windisch to Board of Directors

    CRANBURY, N.J., March 27, 2018-- Oncobiologics, Inc. today announced the appointment of Joerg Windisch, Ph.D. to its board of directors, effective March 23, 2018. In addition, Oncobiologics announced the ...

  • Is Oncobiologics Inc (NASDAQ:ONS) Excessively Paying Its CEO?
    Simply Wall St.3 months ago

    Is Oncobiologics Inc (NASDAQ:ONS) Excessively Paying Its CEO?

    Leading Oncobiologics Inc (NASDAQ:ONS) as the CEO, Pankaj Mohan took the company to a valuation of US$23.68M. Understanding how CEOs are incentivised to run and grow their company is anRead More...

  • Want To Invest In Oncobiologics Inc (NASDAQ:ONS)? Here’s How It Performed Lately
    Simply Wall St.4 months ago

    Want To Invest In Oncobiologics Inc (NASDAQ:ONS)? Here’s How It Performed Lately

    For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Oncobiologics Inc’s (NASDAQ:ONS) track record on a high level, to giveRead More...

  • What You Must Know About Oncobiologics Inc’s (NASDAQ:ONS) Major Investors
    Simply Wall St.4 months ago

    What You Must Know About Oncobiologics Inc’s (NASDAQ:ONS) Major Investors

    In this article, I will take a quick look at Oncobiologics Inc’s (NASDAQ:ONS) recent ownership structure – an unconventional investing subject, but an important one. When it comes to ownershipRead More...

  • Is Oncobiologics Inc’s (NASDAQ:ONS) CEO Paid Enough To Stay Motivated?
    Simply Wall St.6 months ago

    Is Oncobiologics Inc’s (NASDAQ:ONS) CEO Paid Enough To Stay Motivated?

    Pankaj Mohan took the helm as Oncobiologics Inc’s (NASDAQ:ONS) CEO and grew market cap to USD$29.68M recently. Recognizing whether CEO incentives are aligned with shareholders is a crucial part ofRead More...

  • Does Oncobiologics Inc’s (ONS) Recent Track Record Look Strong?
    Simply Wall St.7 months ago

    Does Oncobiologics Inc’s (ONS) Recent Track Record Look Strong?

    For investors with a long-term horizon, assessing earnings trend over time and against industry benchmarks is more valuable than looking at a single earnings announcement in one point in time.Read More...

  • Is Oncobiologics Inc (ONS) Thriving Or Barely Surviving In The Healthcare Sector?
    Simply Wall St.7 months ago

    Is Oncobiologics Inc (ONS) Thriving Or Barely Surviving In The Healthcare Sector?

    Oncobiologics Inc (NASDAQ:ONS), a USD$34.16M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and the growingRead More...

  • Breaking Down Oncobiologics Inc’s (ONS) Ownership Structure
    Simply Wall St.8 months ago

    Breaking Down Oncobiologics Inc’s (ONS) Ownership Structure

    In this analysis, my focus will be on developing a perspective on Oncobiologics Inc’s (NASDAQ:ONS) latest ownership structure, a less discussed, but important factor. A company’s ownership structure is oftenRead More...

  • Capital Cube8 months ago

    ETFs with exposure to Oncobiologics, Inc. : October 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Oncobiologics, Inc. Here are 5 ETFs with the largest exposure to ONS-US. Comparing the performance and risk of Oncobiologics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • ACCESSWIRE9 months ago

    Featured Company News - Oncobiologics Announces Partnership with GMS Tenshi Holdings; Set to Accelerate the Commercialization of Biosimilar Candidates

    Research Desk Line-up: BiondVax Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / September 12, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...

  • Capital Cube10 months ago

    ETFs with exposure to Oncobiologics, Inc. : August 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Oncobiologics, Inc. Here are 5 ETFs with the largest exposure to ONS-US. Comparing the performance and risk of Oncobiologics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)